secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001193125-22-005103
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M
-----------------------------------------------------------------------------

- Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).
- Over 125 start forms submitted; >95% patient compliance; zero meningococcal infections.
- More than 75% of new EMPAVELI starts are switches from competitor Ultomiris.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/0001193125-22-005103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/d232021d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-005103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer